RU2020116903A - Профилактика и лечение реакции "трансплантат против хозяина" с помощью дефензинов - Google Patents

Профилактика и лечение реакции "трансплантат против хозяина" с помощью дефензинов Download PDF

Info

Publication number
RU2020116903A
RU2020116903A RU2020116903A RU2020116903A RU2020116903A RU 2020116903 A RU2020116903 A RU 2020116903A RU 2020116903 A RU2020116903 A RU 2020116903A RU 2020116903 A RU2020116903 A RU 2020116903A RU 2020116903 A RU2020116903 A RU 2020116903A
Authority
RU
Russia
Prior art keywords
defensin
use according
human
seq
defensins
Prior art date
Application number
RU2020116903A
Other languages
English (en)
Russian (ru)
Other versions
RU2020116903A3 (cg-RX-API-DMAC7.html
Inventor
Питер НОРДКИЛД
Original Assignee
Дефенсин Терапьютикс Апс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дефенсин Терапьютикс Апс filed Critical Дефенсин Терапьютикс Апс
Publication of RU2020116903A publication Critical patent/RU2020116903A/ru
Publication of RU2020116903A3 publication Critical patent/RU2020116903A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
RU2020116903A 2017-11-24 2018-11-21 Профилактика и лечение реакции "трансплантат против хозяина" с помощью дефензинов RU2020116903A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17203527 2017-11-24
EP17203527.1 2017-11-24
EP18191954 2018-08-31
EP18191954.9 2018-08-31
PCT/EP2018/082022 WO2019101773A2 (en) 2017-11-24 2018-11-21 Prevention and treatment of graft-versus-host-disease with defensins

Publications (2)

Publication Number Publication Date
RU2020116903A true RU2020116903A (ru) 2021-12-24
RU2020116903A3 RU2020116903A3 (cg-RX-API-DMAC7.html) 2022-04-08

Family

ID=64308771

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020116903A RU2020116903A (ru) 2017-11-24 2018-11-21 Профилактика и лечение реакции "трансплантат против хозяина" с помощью дефензинов

Country Status (15)

Country Link
US (1) US20200291082A1 (cg-RX-API-DMAC7.html)
EP (1) EP3713590B1 (cg-RX-API-DMAC7.html)
JP (1) JP7423523B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200097251A (cg-RX-API-DMAC7.html)
CN (1) CN111741762A (cg-RX-API-DMAC7.html)
AU (1) AU2018371948A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020010180A2 (cg-RX-API-DMAC7.html)
CA (1) CA3083315A1 (cg-RX-API-DMAC7.html)
ES (1) ES3038390T3 (cg-RX-API-DMAC7.html)
MX (1) MX2020005370A (cg-RX-API-DMAC7.html)
PL (1) PL3713590T3 (cg-RX-API-DMAC7.html)
RU (1) RU2020116903A (cg-RX-API-DMAC7.html)
SG (1) SG11202004207VA (cg-RX-API-DMAC7.html)
WO (1) WO2019101773A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202002669B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
KR20230112561A (ko) * 2022-01-20 2023-07-27 가톨릭대학교 산학협력단 간이식환자 장내균총 분석과 이를 통한 이식상태 모니터링과 면역조절 테라그노시스 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US20060115480A1 (en) * 2002-12-19 2006-06-01 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
LT2237799T (lt) 2008-02-01 2019-07-25 Ascendis Pharma A/S Provaistas, apimantis besiskaidantį linkerį
CA2718381A1 (en) * 2008-03-13 2009-09-17 Immuron Limited Colostrum-derived immunoglobulin preparation comprising anti-insulin antibodies for the treatment of metabolic syndrome
CN102159233A (zh) 2008-07-18 2011-08-17 诺维信阿德宁生物技术公司 使用哺乳动物β防御素的炎性肠病的治疗
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブDefensin Therapeutics Aps 炎症性腸疾患の経口治療
ES3010296T3 (en) * 2014-11-25 2025-04-02 Memorial Sloan Kettering Cancer Center Intestinal microbiota and gvhd
CN104971343B (zh) * 2015-07-13 2018-02-02 韩源平 防御素在制备治疗代谢综合征药物方面的应用
ES2871117T3 (es) * 2016-01-26 2021-10-28 Defensin Therapeutics Aps Procedimientos para modular la microbiota intestinal
KR20200095472A (ko) * 2017-11-10 2020-08-10 디펜신 테라퓨틱스 에이피에스 조산아에서의 점막 방어 및 장/폐 기능의 성숙화

Also Published As

Publication number Publication date
KR20200097251A (ko) 2020-08-18
SG11202004207VA (en) 2020-06-29
JP2021504348A (ja) 2021-02-15
WO2019101773A3 (en) 2019-07-04
CA3083315A1 (en) 2019-05-31
BR112020010180A2 (pt) 2021-01-12
JP7423523B2 (ja) 2024-01-29
ZA202002669B (en) 2021-05-26
CN111741762A (zh) 2020-10-02
EP3713590A2 (en) 2020-09-30
EP3713590B1 (en) 2025-05-07
ES3038390T3 (en) 2025-10-13
WO2019101773A2 (en) 2019-05-31
MX2020005370A (es) 2020-10-19
PL3713590T3 (pl) 2025-09-15
EP3713590C0 (en) 2025-05-07
AU2018371948A1 (en) 2020-06-11
US20200291082A1 (en) 2020-09-17
RU2020116903A3 (cg-RX-API-DMAC7.html) 2022-04-08

Similar Documents

Publication Publication Date Title
EP3407905B1 (en) Methods for modulating intestinal microbiota
US9217021B2 (en) Oral treatment of inflammatory bowel disease
CN103476933B (zh) 白介素1受体的拮抗剂
JPH10509737A (ja) サイトカイン調節剤およびサイトカインレベルの変化に関連する病状および状態における使用方法
EP2489362A1 (en) Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
Jin et al. Regulation of oxidative stress in the intestine of piglets after enterotoxigenic Escherichia coli (ETEC) infection
JP4259870B2 (ja) 炎症抑制化合物
WO2015161820A1 (zh) 两亲性合成抗菌肽、其药物组合物及其用途
KR102465341B1 (ko) 간, 담관 및 췌장 장애의 치료
JP2021504348A5 (cg-RX-API-DMAC7.html)
JP6890798B2 (ja) 炎症性腸疾患の予防又は治療用組成物
EP3341006A1 (en) Compositions and methods for the treatment of neurodamage
EP1596879B1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
US9950038B2 (en) Methods and compositions for inhibiting delayed graft function
US10301365B2 (en) Met e 1 tropomyosin variants for use in allergen-specific immunotherapy
WO1997048725A1 (en) Novel peptides for prevention and treatment of infection
Sharma et al. EFFECT OF DONOR AND RECIPIENT AGE AND GENDER ON LIVING DONOR KIDNEY TRANSPLANT: LONG TERM OUTCOME.
ITRM20070481A1 (it) "sequenza peptidica bioattiva da impiegare in sostituzione della calcitonina umana"